ES2644317T3 - Tensioactivos pulmonares reconstituidos - Google Patents
Tensioactivos pulmonares reconstituidos Download PDFInfo
- Publication number
- ES2644317T3 ES2644317T3 ES13807947.0T ES13807947T ES2644317T3 ES 2644317 T3 ES2644317 T3 ES 2644317T3 ES 13807947 T ES13807947 T ES 13807947T ES 2644317 T3 ES2644317 T3 ES 2644317T3
- Authority
- ES
- Spain
- Prior art keywords
- surfactant
- reconstituted
- reconstituted surfactant
- leu
- volumes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003580 lung surfactant Substances 0.000 title 1
- 239000004094 surface-active agent Substances 0.000 description 41
- 239000000203 mixture Substances 0.000 description 21
- 150000003904 phospholipids Chemical class 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 11
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 10
- 235000013345 egg yolk Nutrition 0.000 description 9
- 210000002969 egg yolk Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 102000002322 Egg Proteins Human genes 0.000 description 8
- 108010000912 Egg Proteins Proteins 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 229940092456 curosurf Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 5
- 208000023504 respiratory system disease Diseases 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 108091005461 Nucleic proteins Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 description 3
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 201000005085 Meconium Aspiration Syndrome Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 2
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- DGMGNFWWJGBJGD-VOFYOLNUSA-N P(=O)(O)(O)OCC(CO)O.C(CCCCCCCCCCCCCCC)(=O)OC[C@@H](OCCCCCCCC\C=C/CCCCCCCC)CO Chemical compound P(=O)(O)(O)OCC(CO)O.C(CCCCCCCCCCCCCCC)(=O)OC[C@@H](OCCCCCCCC\C=C/CCCCCCCC)CO DGMGNFWWJGBJGD-VOFYOLNUSA-N 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 206010037370 Pulmonary contusion Diseases 0.000 description 1
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 201000000946 adhesive otitis media Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001849 endotracheal instillation Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000005923 otitis media with effusion Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000024036 serous otitis media Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12193708 | 2012-11-21 | ||
EP12193708 | 2012-11-21 | ||
PCT/EP2013/074312 WO2014079898A1 (en) | 2012-11-21 | 2013-11-20 | Reconstituted pulmonary surfactants |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2644317T3 true ES2644317T3 (es) | 2017-11-28 |
Family
ID=47189830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13807947.0T Active ES2644317T3 (es) | 2012-11-21 | 2013-11-20 | Tensioactivos pulmonares reconstituidos |
Country Status (11)
Country | Link |
---|---|
US (1) | US9074018B2 (xx) |
EP (1) | EP2922868B1 (xx) |
KR (1) | KR102122088B1 (xx) |
CN (1) | CN104812771B (xx) |
AR (1) | AR093569A1 (xx) |
BR (1) | BR112015009486B1 (xx) |
CA (1) | CA2891933C (xx) |
ES (1) | ES2644317T3 (xx) |
HK (1) | HK1211964A1 (xx) |
RU (1) | RU2656185C2 (xx) |
WO (1) | WO2014079898A1 (xx) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101721309B1 (ko) * | 2015-02-23 | 2017-03-30 | 경희대학교 산학협력단 | 계면활성 단백질 b(sp-b) 및 계면활성 단백질 c(sp-c)의 유사체를 포함하는 합성 폐 계면활성제 조성물 |
KR102395835B1 (ko) * | 2016-08-24 | 2022-05-10 | 키에시 파르마슈티시 엣스. 피. 에이. | 재구성된 폐 계면활성제 조성물을 포함하는 안정한 약제학적 제제 |
JP2020500203A (ja) | 2016-11-24 | 2020-01-09 | ウニベルシテイト ヘント | サーファクタントタンパク質bと1つ以上の脂質とを含む粒子 |
CN110099695B (zh) * | 2016-12-22 | 2022-01-25 | 奇斯药制品公司 | 用于治疗进展性bpd的包含肺表面活性物质和类固醇的治疗组合 |
KR101784651B1 (ko) * | 2017-03-15 | 2017-10-13 | 경희대학교 산학협력단 | 계면활성 단백질 b(sp-b) 및 계면활성 단백질 c(sp-c)의 유사체를 포함하는 합성 폐 계면활성제 조성물 |
MX2020006633A (es) * | 2017-12-21 | 2021-01-15 | Civitas Therapeutics Inc | Formulaciones de surfactantes para inhalacion. |
EP4097128A1 (en) | 2020-01-28 | 2022-12-07 | Chiesi Farmaceutici S.p.A. | Polypeptides having improved properties |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1308180B1 (it) | 1999-02-12 | 2001-12-07 | Chiesi Farma Spa | Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante |
ITMI20021058A1 (it) | 2002-05-17 | 2003-11-17 | Chiesi Farma Spa | Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito |
EP1481665A1 (en) * | 2003-05-30 | 2004-12-01 | CHIESI FARMACEUTICI S.p.A. | Novel lipid mixtures for synthetic surfactants |
US7638493B2 (en) * | 2004-04-29 | 2009-12-29 | Sannamu Lee | Artificial pulmonary surfactant compositions and use of the same |
CA2658478C (en) | 2006-07-20 | 2018-02-13 | University Of Rochester | Synthetic lung surfactant and use thereof |
PT2078038E (pt) * | 2006-10-13 | 2013-12-12 | Chiesi Farma Spa | Agentes tensioativos reconstituídos apresentando propriedades melhoradas |
EP2022798A1 (en) | 2007-08-09 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | Synthetic pulmonary surfactant peptides |
US8399406B2 (en) | 2009-06-05 | 2013-03-19 | Chiesi Farmaceutici S.P.A. | Reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C) |
-
2013
- 2013-11-20 WO PCT/EP2013/074312 patent/WO2014079898A1/en active Application Filing
- 2013-11-20 RU RU2015118702A patent/RU2656185C2/ru active
- 2013-11-20 KR KR1020157012783A patent/KR102122088B1/ko active IP Right Grant
- 2013-11-20 BR BR112015009486-4A patent/BR112015009486B1/pt active IP Right Grant
- 2013-11-20 AR ARP130104288A patent/AR093569A1/es not_active Application Discontinuation
- 2013-11-20 CA CA2891933A patent/CA2891933C/en active Active
- 2013-11-20 ES ES13807947.0T patent/ES2644317T3/es active Active
- 2013-11-20 US US14/085,125 patent/US9074018B2/en active Active
- 2013-11-20 EP EP13807947.0A patent/EP2922868B1/en active Active
- 2013-11-20 CN CN201380060505.0A patent/CN104812771B/zh active Active
-
2015
- 2015-12-31 HK HK15112892.7A patent/HK1211964A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR102122088B1 (ko) | 2020-06-12 |
CA2891933A1 (en) | 2014-05-30 |
AR093569A1 (es) | 2015-06-10 |
WO2014079898A1 (en) | 2014-05-30 |
CN104812771A (zh) | 2015-07-29 |
HK1211964A1 (en) | 2016-06-03 |
RU2015118702A (ru) | 2016-12-10 |
BR112015009486A2 (pt) | 2017-09-26 |
BR112015009486B1 (pt) | 2022-06-14 |
US9074018B2 (en) | 2015-07-07 |
CN104812771B (zh) | 2018-03-30 |
KR20150089006A (ko) | 2015-08-04 |
US20140142021A1 (en) | 2014-05-22 |
EP2922868A1 (en) | 2015-09-30 |
EP2922868B1 (en) | 2017-09-27 |
RU2656185C2 (ru) | 2018-05-31 |
CA2891933C (en) | 2022-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2644317T3 (es) | Tensioactivos pulmonares reconstituidos | |
ES2621974T3 (es) | Composición tensioactiva reconstituida mejorada que contiene análogos de proteína tensioactiva B (SP-B) y proteína tensioactiva C (SP-C) | |
EP2152288B1 (en) | Reconstituted surfactants having improved properties | |
ES2253003T3 (es) | Equipo de tratamiento que contiene composiciones a base de agentes tensioactivos pulmonares. | |
ES2278823T3 (es) | Composiciones que comprenden tensioactivos pulmonares y una polimixina que tienen propiedades de superficie mejoradas. | |
KR102395835B1 (ko) | 재구성된 폐 계면활성제 조성물을 포함하는 안정한 약제학적 제제 |